Evolent Health (EVH)
(Delayed Data from NYSE)
$27.65 USD
-0.67 (-2.37%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.65 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
EVH 27.65 -0.67(-2.37%)
Will EVH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EVH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EVH
Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know
EVH: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 5th
How Much Upside is Left in Evolent Health (EVH)? Wall Street Analysts Think 59.66%
Best Momentum Stocks to Buy for November 20th
Other News for EVH
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Evolent Health (EVH) and BioMarin Pharmaceutical (BMRN)
Evolent Health initiated with bullish view at Citi, here's why
In-Depth Examination Of 6 Analyst Recommendations For Evolent Health
Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
Analysts’ Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)